Eylea sales jump helps boost Regeneron in Q2 results
pharmafile | August 5, 2016 | News story | Medical Communications, Research and Development | 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to drive total revenues up by a fifth, compared to the same period in 2015.
Shares at the company, however, fell as the company posted its slowest growth for the last eight quarters.
While US product sales of Eylea rose 27% to $831 million, and total revenues up 21% to $1.2 billion, GAAP net income rose only 1% to $196 million. The macular degeneration drug continues to shine for Regeneron, and the company continues to bet on its success in other indications. Currently, Eylea is being tested alongside PDGF receptor antibody rinucumab in wet age-related macular degeneration. This combination holds the FDA fast track designation.
In terms of its current pipeline, Regeneron currently has 15 product candidates in clinical development, with their ongoing collaboration with Sanofi offering promising signs. After Phase III trials which said that sarilumab performed better than Humira (adalimumab) in rheumatoid arthritis, both the FDA and the EMA have accepted marketing applications for review. Treatments for atopic dermatitis and advanced cutaneous squamous cell carcinoma were also either in late-stage trials, or undergoing regulatory review.
As a whole, collaborations continue to yield strong revenues for the company, with total revenue from the Sanofi collaboration rising 4% to $383,108 and the Bayer collaboration rising 44% to $371,488.
Leonard S. Schleifer, CEO at Regeneron, says: “In the first half of this year, Eylea continued to demonstrate strong sales growth, and Praluent sales made steady progress as healthcare providers become more familiar with this new therapeutic class and learn to navigate payer utilisation management criteria.”
Sean Murray
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Dupixent improves symptoms in patients with skin of colour, study shows
Sanofi and Regeneron have announced results from the collaborative phase 4 DISCOVER study, presented at …
Dupixent approved as first biologic medicine in Japan for COPD patients
The Ministry of Health, Labour and Welfare in Japan has authorised marketing and manufacturing of …
